335 related articles for article (PubMed ID: 25157953)
21. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
22. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.
Yun C; Gang L; Rongmin G; Xu W; Xuezhi M; Huanqiu C
Mol Carcinog; 2015 Dec; 54(12):1700-9. PubMed ID: 25400108
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Hirsch FR; Varella-Garcia M; Cappuzzo F
Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
[TBL] [Abstract][Full Text] [Related]
24. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S
Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363
[TBL] [Abstract][Full Text] [Related]
25. The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer.
Kim ST; Do IG; Lee J; Sohn I; Kim KM; Kang WK
Clin Transl Oncol; 2015 Jun; 17(6):462-8. PubMed ID: 25445175
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix.
Ueda A; Takasawa A; Akimoto T; Takasawa K; Aoyama T; Ino Y; Nojima M; Ono Y; Murata M; Osanai M; Hasegawa T; Saito T; Sawada N
PLoS One; 2017; 12(8):e0184123. PubMed ID: 28859123
[TBL] [Abstract][Full Text] [Related]
27. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers.
Lee J; Kim S; Kim P; Liu X; Lee T; Kim KM; Do IG; Park JO; Park SH; Jang J; Hoe N; Harvie G; Kuller A; Jain A; Meyer G; Leesman G; Park YS; Choi MG; Sohn TS; Bae JM; Lim HY; Singh S; Kang WK
PLoS One; 2013; 8(1):e54644. PubMed ID: 23372746
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
[TBL] [Abstract][Full Text] [Related]
29. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
30. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma.
Mataki H; Seki N; Chiyomaru T; Enokida H; Goto Y; Kumamoto T; Machida K; Mizuno K; Nakagawa M; Inoue H
Int J Oncol; 2015 Mar; 46(3):1039-50. PubMed ID: 25522678
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer.
Kurokawa Y; Matsuura N; Kawabata R; Nishikawa K; Ebisui C; Yokoyama Y; Shaker MN; Hamakawa T; Takahashi T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S584-90. PubMed ID: 24743909
[TBL] [Abstract][Full Text] [Related]
32. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
[TBL] [Abstract][Full Text] [Related]
33. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
34. Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.
Lee JM; Lee SH; Hwang JW; Oh SJ; Kim B; Jung S; Shim SH; Lin PW; Lee SB; Cho MY; Koh YJ; Kim SY; Ahn S; Lee J; Kim KM; Cheong KH; Choi J; Kim KA
Oncogene; 2016 Aug; 35(34):4437-46. PubMed ID: 26853467
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
[TBL] [Abstract][Full Text] [Related]
36. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
37. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
39. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
[TBL] [Abstract][Full Text] [Related]
40. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.
Goltsov AA; Fang B; Pandita TK; Maru DM; Swisher SG; Hofstetter WL
Ann Thorac Surg; 2018 Feb; 105(2):363-370. PubMed ID: 29223420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
